Bio-economy news

Subscribe to Bio-economy news feed Bio-economy news
Business Wire - The global leader in news distribution
Updated: 47 min 45 sec ago

Anokion Expands Leadership Team with Appointment of Simon Cooper, MBBS, as Chief Medical Officer

47 min 45 sec ago
LAUSANNE, SWITZERLAND, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anokion (“Anokion” or the “Company”), a leading immune tolerance company advancing novel, antigen-specific treatments for autoimmune disease, today announced that Simon Cooper, MBBS., has been appointed to the newly created position of chief medical officer. Dr. Cooper will lead Anokion’s team that is advancing the company’s development pipeline into clinical testing, with the first trial expected to commence by late 2019. Dr. Cooper w

Newron Pharmaceuticals: Commercialization Partner Zambon Together with Valeo Pharma Announce the Approval of Onstryv® (safinamide) for Parkinson’s Disease in Canada

1 hour 47 min ago
MILAN--(BUSINESS WIRE)--lt;a href="" target="_blank"gt;$NWRNlt;/agt; lt;a href="" target="_blank"gt;#Parkinsonslt;/agt;--Newron Pharmaceuticals' partner Zambon, together with Valeo Pharma, announce the approval of Onstryv® (safinamide) for Parkinson’s disease in Canada.

Argentum Electronics Wins N100, Secures $250,000 Investment

Tue, 15/01/2019 - 12:00
COBOURG, Ontario--(BUSINESS WIRE)--lt;a href="" target="_blank"gt;#N1002018lt;/agt;--Northumberland CFDC today announced that Argentum Electronics is the winner of its 2018 $250,000 N100 Evolution technology startup competition. The multi-stage competitive gauntlet began in July 2018 at Venture13 in Cobourg, with a total of 44 startups competing at the outset. Argentum Electronics has designed a product line of Power-over-Ethernet (PoE) technologies and smart power management solutions, working within an ecosystem of innovative architects, bui

New Diverse Field Crops Cluster Goal to Increase Cropping Options for Farmers

Tue, 15/01/2019 - 11:00
SASKATOON, Saskatchewan--(BUSINESS WIRE)--A new Diverse Field Crops Cluster has received over $13 million in federal funding.

AmorChem, KNOCK OUT Event, 5th round

Tue, 15/01/2019 - 08:00
MONTREAL--(BUSINESS WIRE)--lt;a href="" target="_blank"gt;#amorchemlt;/agt;--Back by popular demand, AmorChem is hosting its fifth KNOCK OUT Event during the 1st edition of the EFFERVERSCENCE conference, April 24th, 2019 in Montreal. Researchers selected to participate in the Dragons’ Den inspired AmorChem KNOCK OUTTM Event will fight it out in the ring against our panel of “heavyweights” eager to defend their title. If you are an academic life science researcher with an appetite to KNOCK OUT the competition, if you have innovative science wit

Valeo Pharma and Zambon announce the approval of Onstryv® (safinamide) for Canada

Tue, 15/01/2019 - 08:00
BRESSO, Italy--(BUSINESS WIRE)--Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, and Valeo Pharma Inc., a specialty pharmaceutical company dedicated to commercializing innovative prescription products in Canada, today announce the approval of Onstryv® (safinamide) for the treatment of Parkinson’s Disease in Canada. Under the terms of the agreement with Zambon, Valeo Pharma is responsible for all regulatory, quality,

QIAGEN’s QuantiFERON®-TB Gold Plus Gains Approval in Canada

Mon, 14/01/2019 - 17:00
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--lt;a href="" target="_blank"gt;$QGENlt;/agt;--QIAGEN’s QuantiFERON®-TB Gold Plus gains approval in Canada

Peer-Reviewed Paper Featuring Titan Medical’s Single-Port Robotic Surgical Platform in General Surgery Published in Surgical Endoscopy

Mon, 14/01/2019 - 10:00
TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (TSX: TMD) (Nasdaq: TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), announces that a peer-reviewed multi-faculty paper featuring Titan’s single-port platform has been published in the January 2019 issue of Surgical Endoscopy. The paper highlights the feasibility, safety and ease of use of Titan’s single-port

FSD Pharma Congratulates Cannara Biotech for Its Listing and Commencement of Trading on the CSE

Mon, 14/01/2019 - 09:00
TORONTO--(BUSINESS WIRE)--lt;a href="" target="_blank"gt;#FSDDFlt;/agt;--FSD Pharma Inc. ("FSD" or the "Company") (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) would like to congratulate Cannara Biotech Inc. (“Cannara”) for its listing approval and commencement of trading on the Canadian Securities Exchange ("CSE") today under the stock symbol "LOVE". FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares ("Common Shares") of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer. Antho

AmorChem Invests in Groundbreaking RNA Technology

Mon, 14/01/2019 - 08:00
MONTRÉAL--(BUSINESS WIRE)--lt;a href="" target="_blank"gt;#amorchemlt;/agt;--AmorChem II is proud to announce the closing of its first financing of a university project. The venture capital fund has reached an agreement with Univalor, Dr Éric Lécuyer of the Montreal Clinical Research Institute (“IRCM”), Dr. Mathieu Blanchette and Dr. Jérôme Waldispühl of McGill University to collaborate on a project focusing on short sequences of RNA that direct intracellular traffic (“RNA Zipcodes”). “Recent years have seen a resurgence in the development of

Acerus Announces Reporting of Anticipated Shortage of ESTRACE®

Fri, 11/01/2019 - 19:00
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) is today advising that it has reported an anticipated shortage of certain doses of ESTRACE® on the Drug Shortages Canada website in relation to supply issues arising from the Company’s contract manufacturer. The Company had previously been notified by its contract manufacturer of a partial manufacturing license suspension at the facility where ESTRACE® is being produced as a result of an audit by

Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada

Fri, 11/01/2019 - 09:00
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology and Knight Therapeutics have entered into an exclusive license agreement to commercialize NERLYNX® (neratinib) in Canada.

Bioasis Announces the Appointment of Christine Antalik as Chief Financial Officer

Wed, 09/01/2019 - 09:00
GUILFORD, Conn.--(BUSINESS WIRE)--lt;a href="" target="_blank"gt;$BIOAFlt;/agt; lt;a href="" target="_blank"gt;#BBBlt;/agt;--Bioasis announces the appointment of Christine Antalik as chief financial officer.

LEO Pharma Strengthens Focus on Translational Medicine with the Appointment of Adam B. Raff, M.D., Ph.D., as Director and Medical Advisor

Wed, 09/01/2019 - 05:00
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma, a global leader in medical dermatology, today announced that Adam B. Raff has been appointed as Director and Medical Advisor in Translational Medicine as of January 28, 2019. Adam Raff’s primary objective will be to support LEO Pharma’s ambitions to advance science within dermatology through translational medicine. Adam Raff is a Doctor of Medicine (Hons) and holds a Doctorate in Philosophy in Systems Biology and Disease from the University of Sou

Mobi Is Here: ResMed’s First Portable Oxygen Device Now Widely Available in the U.S.

Tue, 08/01/2019 - 10:00
SAN DIEGO--(BUSINESS WIRE)--lt;a href="" target="_blank"gt;$RMDlt;/agt; lt;a href="" target="_blank"gt;#COPDlt;/agt;--ResMed's Mobi portable oxygen concentrator, part of its growing COPD product portfolio, offers an optimal balance of oxygen, battery life and weight.

Introducing ZYUS Life Sciences Inc., The Next Global Leader in Phyto-Therapeutics and Medical Cannabis Derivative Products

Mon, 07/01/2019 - 14:00
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Introducing ZYUS - The Next Global Leader in Phyto-Therapeutics and Medical Cannabis Derived Products

Bioasis Announces Agreement With Leading Pharmaceutical Company for Pre-Clinical Research Using the xB3 Platform Technology

Mon, 07/01/2019 - 09:00
GUILFORD, Conn.--(BUSINESS WIRE)--lt;a href="" target="_blank"gt;$BIOAFlt;/agt; lt;a href="" target="_blank"gt;#BBBlt;/agt;--Bioasis announces agreement with leading pharmaceutical company for pre-clinical research using the xB³ platform technology.

Genevant Appoints Dr. Margrit Schwarz as Chief Scientific Officer and Head of R&D, and Pete Zorn as Chief Operating Officer

Mon, 07/01/2019 - 08:00
BOSTON & BURNABY, British Columbia & BASEL, Switzerland--(BUSINESS WIRE)--lt;a href="" target="_blank"gt;#RNAlt;/agt;--Genevant Appoints Dr. Margrit Schwarz as Chief Scientific Officer and Head of R&D, and Pete Zorn as Chief Operating Officer

Zymeworks Highlights 2018 Achievements and Announces 2019 Priorities

Sun, 06/01/2019 - 07:00
VANCOUVER, Canada--(BUSINESS WIRE)--Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reviewed its key 2018 accomplishments and outlined the Company’s priorities for 2019. “With our clinical, preclinical, and business development achievements in 2018, along with a robust balance sheet, we believe we are in a strong position to continue delivering on our corporate objectives in 2019 and beyond,” said Ali Tehrani, Ph.D.,

Generex Biotechnology Provides Update on NuGenerex Immuno-Oncology

Fri, 04/01/2019 - 10:00
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to provide an update on operational and strategic developments at NuGenerex Immuno-Oncology (previously Antigen Express), a wholly-owned subsidiary. The protocol for the Phase II clinical trial of pembrolizumab (Keytruda®) in combination with the AE37 Peptide Vaccine in patients with metastatic triple negative breast cancer is under review at the Institutional Review Board (IRB) with oversight of this NSAB